<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>17</volume><submitter>Scherer TP</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Transurethral resection of the bladder (TURB) harbors a high-risk for postoperative bleeding, especially in patients requiring anticoagulation. Recently, direct oral anticoagulants (DOACs) have become a popular alternative to vitamin K antagonists (VKAs), though their impact on TURB complications remains unclear.&lt;h4>Objectives&lt;/h4>To assess the postoperative complications of TURB from patients taking DOACs and VKAs.&lt;h4>Design&lt;/h4>Retrospective cohort study.&lt;h4>Materials and methods&lt;/h4>We retrospectively identified anticoagulated patients undergoing a TURB at our institution between 2012 and 2022 and divided them into two groups: whether they received VKA or DOAC. Follow-up of each patient was performed for 3 months. Occurrence and time to event of postoperative bleeding</pubmed_abstract><journal>Therapeutic advances in urology</journal><pagination>17562872251315930</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11792014</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Risk of postoperative bleeding and thromboembolic events in anticoagulated patients undergoing transurethral resection of bladder tumors.</pubmed_title><pmcid>PMC11792014</pmcid><pubmed_authors>Bieri U</pubmed_authors><pubmed_authors>Scherer TP</pubmed_authors><pubmed_authors>Dam C</pubmed_authors><pubmed_authors>Strebel R</pubmed_authors><pubmed_authors>Eberli D</pubmed_authors></additional><is_claimable>false</is_claimable><name>Risk of postoperative bleeding and thromboembolic events in anticoagulated patients undergoing transurethral resection of bladder tumors.</name><description>&lt;h4>Background&lt;/h4>Transurethral resection of the bladder (TURB) harbors a high-risk for postoperative bleeding, especially in patients requiring anticoagulation. Recently, direct oral anticoagulants (DOACs) have become a popular alternative to vitamin K antagonists (VKAs), though their impact on TURB complications remains unclear.&lt;h4>Objectives&lt;/h4>To assess the postoperative complications of TURB from patients taking DOACs and VKAs.&lt;h4>Design&lt;/h4>Retrospective cohort study.&lt;h4>Materials and methods&lt;/h4>We retrospectively identified anticoagulated patients undergoing a TURB at our institution between 2012 and 2022 and divided them into two groups: whether they received VKA or DOAC. Follow-up of each patient was performed for 3 months. Occurrence and time to event of postoperative bleeding</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Jan-Dec</publication><modification>2025-04-22T12:36:33.515Z</modification><creation>2025-04-06T00:26:20.432Z</creation></dates><accession>S-EPMC11792014</accession><cross_references><pubmed>39906152</pubmed><doi>10.1177/17562872251315930</doi></cross_references></HashMap>